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Abstract
Background: Clostridium difficile infection (CDI) has increased in incidence and severity over the past quarter
century, and is now considered a major cause of healthcare-associated infections.
Methods: Review of the pertinent English-language medical literature.
Results: There has been a substantial change in the management of CDI. The emergence of the NAP1/BI/O27
strain in the early to mid-2000s has been associated with more severe forms of CDI. The pathophysiology,
epidemiology, clinical manifestations and diagnosis, as well as new strategies for medical and surgical man-
agement are discussed in this review.
Conclusions: Clostridium difficile infection can range from benign diarrhea to severe disease associated with
substantial morbidity and mortality. Treatment modalities vary based on disease severity and timing of onset.
The mainstay of medical treatment remains metronidazole and oral/rectal vancomycin. New management
strategies are evolving, including adjunctive treatments such as monoclonal antibodies, vaccination, and fecal
transplant. In patients with severe disease or clinical deterioration, early surgical consultation for total colectomy
or loop ileostomy may be life-saving. Infection control measures are vital to mitigating the spread of CDI.
During the past 20 years, the incidence and severityof Clostridium difficile infections have increased dra-
matically, especially with the emergence of the NAP1/BI/
O27 strain in the early-to-mid-2000s. Clostridium difficile is
now considered one of the most important causes of health-
care-associated infections, and community-acquired C. diffi-
cile disease also has emerged as an important entity. Both
medical and surgical management of C. difficile colitis have
changed over the past decade. This review provides an update
regarding pathophysiology, epidemiology, clinical manifes-
tations and diagnosis, current medical and surgical manage-
ment, and opportunities for advancement in treatment
modalities for C. difficile infection (CDI).
Pathophysiology
Clostridiumwas first cultured by Hall and O’Toole in 1935
from the feces of healthy newborns [1]. It was named ‘‘Ba-
cillus difficilis’’ due to the difficulty in culturing this slow-
growing, gram-positive bacillus from an anaerobic medium.
While of academic interest, the C. difficile bacterium was not
believed to be important clinically significant until the late
1970s, when its pathogenic role in antibiotic-associated di-
arrhea and pseudomembranous colitis was described [2]. We
now know that C. difficile is a rod-shaped sporulating, an-
aerobic gram-positive bacillus whose potent toxins can cause
symptoms ranging from mild diarrhea to life-threatening
pseudomembranous colitis and toxic megacolon. Its viru-
lence is related to the production of endospores and endo-
toxins A and B.
The life cycle of the C. difficile bacterium is shown in
Figure 1 [3]. Transmission occurs via ingestion of spores
and vegetative cells. Most of the vegetative cells are killed
by gastric acid. The spores, on the other hand, can survive
the acidic gastric environment and will germinate in the
small bowel upon exposure to bile acids. These newly
flagellate bacteria then migrate to the colon where they can
multiply, especially in the setting of antibiotic-induced
changes to the composition of colonic flora. The bacteria
adhere to the gut mucosa and produce toxins A and B, which
leads to a massive inflammatory response cascade, epithe-
lial cell junction opening and apoptosis, and degradation
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of connective tissue by hydrolytic enzymes. The end result
is the development of pseudomembranous colitis and wa-
tery diarrhea.
Clostridium difficile can be part of the normal colon flora
colonizing the colon of an asymptomatic carrier. However,
when there is an alteration to the composition of normal
colonic flora, it can lead to organism overgrowth and toxin
elaboration. Kyne et al. showed that as many as 31% of pa-
tients who received antibiotics were colonized with C. diffi-
cile, and 56% of these patients subsequently developed
symptomatic C. difficile disease [4].
The C. difficile bacterium produces two distinct toxins.
Toxin A is an enterotoxin that causes local tissue damage and
fluid secretion along with the inflammatory response. This is
the less potent of the two toxins produced. Toxin B activates
the release of cytotoxins from monocytes, leading to the
destruction of the cytoskeleton. Toxin B is approxima-
tely 1,000 times more potent than toxin A. In some strains of
FIG. 1. Lifecycle of the Clostridium difficile bacterium. From Poutanen and Simor [3].
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C. difficile, the tcd-A and tcd-B genes also produce a binary
toxin, the clinical implications of which are as yet uncertain.
Classification and Definitions
Clostridium difficile infection is associated commonly with
diarrhea, defined as ‡ 3 stools in less than 24 h. However, the
lack of diarrhea does not preclude a CDI, as approximately 1%
of patients may present with ileus and colonic distention rather
than diarrhea. Symptoms may vary from mild diarrhea treated
on an outpatient basis to fulminant severe colitis requiring mul-
timodal therapy, intensive care unit (ICU) support, and possible
diverting ileostomy or total abdominal colectomy. Extent and
duration of CDI treatment is based on clinical severity.
Most patients with CDI will have a recent history of an-
timicrobial or antineoplastic treatment. However, there are
increasing reports of cases from the community that have not
been preceded by antimicrobial use. For epidemiologic sur-
veillance, distinction is made between community-onset,
community-associated, healthcare facility-onset and health-
care facility–associated CDI. Cases where symptom onset
or exposure setting do not fit criteria or cannot be determined
are classified as ‘‘indeterminate’’ or ‘‘unknown,’’ respectively.
Detailed criteria for classification are listed in Table 1 and
Figure 2 [5].
Epidemiology
Prior to the 2000s, the rate of CDI did not vary much from
year to year. However, in the past decade and a half, the total
number of cases reported has increased dramatically by ap-
proximately 25% per year. During the mid- and late-1990s, the
reported incidence of CDI in acute care hospitals in the United
Stateswas stable at 30 to 40 cases per 100,000 population, with
an increase to 50/100,000 cases in 2001 and 84/100,000 cases
in 2005—nearly three times the baseline rate of 31/100,000 in
1996 [6]. The incidence and severity of CDI has been on the
increase over the last 10 to 20 years, and it is described in-
creasingly outside healthcare settings and in populations pre-
viously believed to be at low risk [7].
There also has been a substantial increase in the morbidity,
mortality and economic burden associated with CDI in the
last several years [8,9]. Increasing rates of severe and fatal
infections are of great concern. Clostridium difficile infection
was reported as the primary cause of death in England for 499
patients in 1999; this number increased to 2,998 in 2005 and
3,933 in 2006 [10]. The 2003 outbreak in Quebec, Canada was
notable, with a reported four-fold increase in the incidence of
CDI from 22.2 and 25.2 per 100,000 population (in 1991 and
2002, respectively) to 92.2 per 100,000 in 2003 [11]. This
outbreak was associated with major mortality, with C. difficile
as the attributable cause of death in 6.9% of cases and as a
contributing factor in an additional 7.5% of cases [12].
A recent multicenter study documented that CDI is a
common nosocomial infection in mechanically-ventilated
ICU patients (n= 386; 6.6% of a total cohort of 5,852 pa-
tients), and that septic shock occurred in 34.7% of patients.
For C. difficile patients, the mortality rate was high (25.1%)
and prolonged hospital (23 d vs. 15 d; p < 0.001) and ICU
(12 d vs. 8 d; p< 0.001) length of stay (LOS) were noted, with
increased need for skilled nursing care or rehabilitation fol-
lowing hospital discharge [13].
A major contributor to this increase was the emergence of
a new strain of C. difficile, the toxigenic strain III NAP1/BI/
O27. Between 2002 and 2006, this particular strain gained
FIG. 2. Timeline for surveillance definitions of Clostridium difficile–associated infection (CDI) exposures.
A case patient who had symptom onset during the window of hospitalization marked by an asterisk (*) would be classified
as having community-onset, healthcare facility–associated disease (CO-HCFA) if the patient had been discharged from a
healthcare facility within the previous four weeks; would be classified as having indeterminate disease if the patient had
been discharged from a healthcare facility within the previous four to 12 weeks; or would be classified as having com-
munity-associated CDI (CA-CDI) if the patient had not been discharged from a healthcare facility in the previous 12 weeks.
HO-HCFA = healthcare facility-onset, healthcare facility–associated CDI. From Conen et al. [15].
Table 1. Classification of Clostridium difficile Infection (CDI) Based on Exposure Setting and Timing
Disease
classification Definition
HCF onset, HCF-
associated CDI
Symptom onset ‡ 48 h after admission and before discharge from a HCF
Community onset,
HCF-associated CDI
Symptom onset in the community or within 48 h of admission to a HCF,
provided symptom onset was £ 4 weeks after the last discharge from a HCF.
Community-
associated CDI
Symptom onset in the community or within 48 h of admission to an HCF,
provided symptom onset was > 12 weeks after the last discharge from a HCF.
Indeterminate CDI Symptom onset does not fit any of the above criteria for an exposure setting
Unknown CDI Exposure setting cannot be determined because of lack of available data
From: McDonald et al. [4].
HCF= healthcare facility.
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public notoriety as the cause of a deadly new epidemic; as of
2010 this strain has spread to 40U.S. states, seven Canadian
provinces, as well as England, continental Europe, and Asia
[14,15]. The NAP1 strain is associated with the use of fluor-
oquinolones, and contains an 18-pair deletion as well as a
novel single-base deletion in the tcd-C gene, which results in
overproduction of toxins A and B, as well as the emergence of
a binary toxin whose clinical significance has not been eluci-
dated yet [16,17]. Clinically, patients manifest more severe
cases of CDI, with more presentations of toxic megacolon than
diarrhea, profound leukemoid reactions, severe hypoalbumi-
nemia, septic shock, and increased mortality. A recent analysis
identified the key genetic changes linked to the rapid trans-
continental dissemination of this epidemic C. difficile and its
spread throughout the global healthcare system [18].
Epidemiologic data confirm that CDI also is increasing in
surgical patients in the United States, with a 34% increase
over a 5-y period (1999–2003). In particular, CDI was most
prevalent after emergency surgery and among patients having
intestinal tract resections. Multivariable analysis demon-
strated that C. difficile was an independent predictor of LOS,
which increased by 16.0 d, (95% confidence interval [CI]
15.6–16.4; p < 0.0001) in the presence of infection. Total
charges increased by $77,483 (95% CI $75,174-$79,793;
p < 0.0001), and there was a 3.4-fold increase in the mortality
rate (95% CI 3.02–3.77; p < 0.0001), compared with patients
who did not acquire C. difficile [19].
The 2010 clinical practice guidelines for C. difficile in-
fection in adults—published by the Society for Healthcare
Epidemiology of America (SHEA) and the Infectious Dis-
ease Society of America (IDSA)—make the following evi-
dence-based recommendations with regard to epidemiologic
surveillance for CDI: To increase comparability between
clinical settings, use available standardized case definitions
for surveillance of 1) healthcare facility (HCF)-onset, HCF-
associated CDI, 2) community-onset, HCF-associated CDI,
and 3) community-associatedCDI (Fig. 2; strength of evidence
and recommendation B-III); at a minimum, conduct surveil-
lance for HCF-onset, HCF-associated CDI in all inpatient
healthcare facilities, to detect outbreaks and monitor patient
safety (B-III); express the rate of healthcare-associated CDI as
the number of cases per 10,000 patient-days (B-III); and if CDI
rates are high, compared with those at other facilities, or if an
outbreak is noted, stratify rates by patient location in order to
target control measures (B-III).
Risk Factors
Classically, any exposure to antibiotics (particularly clin-
damycin, ampicillin or amoxicillin, cephalosporins and fluor-
oquinolones) was a major risk factor for the development of
CDI. However, there has been emergence of community-
acquired CDI where antimicrobial exposure does not precede
clinical infection. Age older than 65 y alone confers a 16.3-fold
risk for development of CDI. Increased length of hospital stay,
manipulation of the gastrointestinal tract (e.g., surgery), im-
munosuppressed state (e.g., chemotherapy, HIV+ patients, and
medical comorbidities leading to immunosuppression) also
make the patientmore susceptible to developingCDI. There also
has been much debate regarding the role of acid-suppressive
medications such as histamine-2 receptor antagonists and proton
pump inhibitors in the development of CDI [20–22].
Clinical Manifestations
The spectrum of CDI ranges from the asymptomatic car-
rier (found in 7–26% of adults in acute care facilities) to mild/
moderate diarrhea to fulminant colitis and pseudomem-
branous colitis resulting in multiple organ dysfunction syn-
drome and death. Infection can manifest as multiple loose
stools with passage of mucus or occult in milder cases of
CDI; frank melena or hematochezia are rare. With more se-
vere forms of CDI, patients may develop unexplained pro-
found leukocytosis, colonic ileus, or toxic megacolon seen on
abdominal imaging with minimal to no diarrhea. The NAP1/
BI/O27 strain of C. difficile has been associated with these
more severe clinical manifestations of CDI in major out-
breaks around the world [17].
Diagnosis
Laboratory studies
The diagnostic tests of choice are either a stool sample
positive for C. difficile or its toxins, or colonoscopic/histo-
pathologic findings of pseudomembranous colitis. According
to the 2010 SHEA/IDSA clinical practice guidelines, the gold
standard for diagnosis of CDI is with toxigenic stool culture;
however, this is not practical for routine diagnosis and has
been recommended for epidemiologic studies only. Stool
samples should only be collected from symptomatic patients
with diarrhea unless colonic ileus is suspected. The re-
commended route for testing is the use of a two-step algorithm,
Table 2. Diagnostic Testing for Clostridium difficile
Test Sensitivity Specificity Availability Expensea Utilization
C. difficile
culture
Low Moderate Limited $5–10 No diagnostic use; only toxigenic organisms
cause disease
Toxigenic
culture
High High Limited $10–30 Reference method epidemiologic tool
Limited diagnostic use
CCNA High High Limited $15–25 Reference method, limited diagnostic use
GDH High Low Wide $5–15 Diagnostically as a screening test; must be confirmed
Toxin EIA tests Low High Wide $5–15 Must detect toxins A +B; inferior sensitivity
NAATs High High Wide $20–50 Use only in acute disease; false-positives of concern
From Surawicz et al. [25]. (Reprinted by permission from Macmillan Publishers Ltd.).
aCost of goods; does not reflect laboratory changes.
CCNA =C. difficile cytotoxin neutralization assay; GDH = glutamate dehydrogenase; EIA = enzyme immunoassay; NAATs = nucleic acid
amplification tests.
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which employs a glutamine dehydrogenase (GDH) assay for
the C. difficile antigen, followed by enzyme immunoassay
(EIA) toxin testing. If the antigen is positive and toxin is
negative, some laboratories will send the specimen for
polymerase chain reaction (PCR) testing as a final confir-
matory step. Nucleic acid amplification tests (NAATs) such
as PCR are superior to EIA in terms of sensitivity and spec-
ificity (Table 2) but are much more costly, and false positives
may result in inappropriate treatment. It is important to note
that when results are negative, repeat testing is of limited
value [23–25]. Furthermore, testing for cure is not re-
commended.
Adjunctive studies
In cases where index of suspicion is high in the absence of
a diarrheal specimen for laboratory testing, endoscopic
evaluation of the colon may be helpful. The classic endo-
scopic description is of normal-to-patchy, nonspecific colitis
with inflamedmucosa studded with adherent raised white and
yellow plaques (Fig. 3, Panel A), but nodular C. difficile
colitis has also been reported (Fig. 3, Panel B) [26,27]. It is
important to note that the false-negative rate for endoscopy
may be as high as 10–25%. Also, in patients suspected of
having fulminant colitis and toxic megacolon, there is an
increased risk for perforation during endoscopic evaluation.
Radiologic evaluation may be useful adjuncts in evaluating
the critically ill patient for possible CDI. Plain abdominal
x-rays may show dilated colon consistent with toxic mega-
colon. Computed tomography (CT) may show ‘‘thumbprint-
ing’’ of the mucosa indicative of colonic mucosal edema, wall
thickening, abnormal bowel wall attenuation (target sign),
nodular fold thickening, the ‘‘accordion’’ sign (alternating
edematous haustral folds separated by transverse mucosal
ridges filled with enteral contrast material), fat stranding, or in
severe cases, ascites or perforation. Overall computed tomo-
graphy (CT) sensitivity is 52–85%, with specificity of 48–93%
[28,29]. Some institutions advocate more rigid adherence to
CT scan diagnostic criteria for C. difficile colitis of colon wall
thickening of greater than 4mm combined with any one or
more findings of pericolonic stranding, colon wall nodularity,
the ‘‘accordion’’ sign, or otherwise unexplained ascites, with a
reported sensitivity of 70% and specificity of 93% [30].
Medical Management
Current standard of care
The first step in treatment ofC. difficile disease is cessation
of all antibiotics if possible. Prompt appropriate fluid resus-
citation, electrolyte normalization, discontinuation of all
antiperistaltic agents (including narcotics) that inhibit the
elimination of intestinal luminal toxin, and correction of any
other concomitant organ dysfunction remain the initial
mainstay of therapy in C. difficile disease.
According to the 2010 SHEA/IDSA guidelines, metroni-
dazole is the initial drug of choice for the treatment of mild-
to-moderate CDI, with oral vancomycin reserved for more
severe cases, and the addition of vancomycin retention ene-
mas in severe or complicated cases of CDIs (Table 3A)
[15,31]. Numerous studies have examined the efficacy of
metronidazole versus oral vancomycin for the treatment of
CDI. Vancomycin is one of only two U.S. Food and Drug
Administration (FDA)-approved drug for the treatment of
CDIs, and overall has a higher rate of cure, especially in more
severe cases of CDI. Oral vancomycin also has a lower treat-
ment failure rate, as there is evidence of someC. difficile strains
showingmetronidazole resistance in vitro. However, formilder
cases of CDI, the difference between the two drugs is marginal
(96% for vancomycin and 90% for metronidazole); thus, due to
concerns regarding cost and potential emergence of vanco-
mycin-resistant Enterococcus, metronidazole is still the pre-
ferred initial agent for these milder infections [17,32–34].
In patients with a first recurrence of CDI, the recommended
treatment algorithm is the same as for the index episode;
however, for patients with multiple recurrences, oral– rectal
vancomycin in a tapered or pulsed regimen is recommended
due to concern for neurotoxicity from cumulative metronida-
zole dosing (Table 3B; Fig. 4; Fig. 5) [14,28,32].
Alternative medications and adjunctive therapies
New treatment strategies for CDI are needed, and impor-
tant data have emerged recently for new anti-C. difficile an-
tibiotics including fidaxomicin, rifampin, rifaximin, rifalazil,
nitazoxanide, tigecycline, and ramoplanin [36,37].
Fidaxomicin
Fidaxomicin (OPT-80) is a macrocyclic antibiotic with a
narrow antimicrobial spectrum. Most of its activity is
against C. difficile, most strains of staphylococci, and
FIG. 3. Findings of Clostridium difficile colitis. (Courtesy
of Dr. Julio Murra-Saca, Hospital Centro de Emergencias
[26]; Reprinted with permission from Medscape [27].)
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enterococci. It is active against clinical isolates of C. diffi-
cile, including the NAP1/BI/027 strains. As with oral van-
comycin, there is minimal systemic absorption when the
drug is given orally, with resultant high fecal concentra-
tions. In vitro and in vivo studies also show limited activity
against other components of the normal gut flora. The first
published report of fidaxomicin efficacy was a randomized
(n = 629) trial comparing fidaxomicin (200mg twice daily)
or vancomycin (125mg four times daily) orally for 10 d.
The rates of clinical cure were non-inferior, but fidaxomicin
was associated with a significantly lower rate of recurrence
of CDI in patients with the NAP1 strain (15% vs. 25% in
modified intention-to-treat population; p = 0.005) [38,39].
In a multicenter, multinational, double-blind randomized
controlled trial (n = 535) of fidaxomicin versus oral vanco-
mycin, fidaxomicin was shown to have similar rates of
clinical cure as oral vancomycin, with improved sustained
response and decreased recurrence rates [40]. Fidaxomicin
has recently received FDA approval for the treatment of
CDI with a recommended treatment dose of 100mg by
mouth (PO) twice daily (BID).
Rifampin
Rifampin displays potent activity againstC. difficile strains
but resistance remains a concern. In a study of C. difficile
strains from hospitalized patients, 12 of 163 isolates were
resistant to rifampin [41] and in a single-center Pittsburgh
study, 36.8% (173–470) strains displayed reduced suscepti-
bility to rifampin [42]. In a clinical study of metronidazole
monotherapy versus metronidazole/rifampin combination
therapy, no difference in median time to resolution of
symptoms or median time to first occurrence of relapse was
identified in an interim analysis, and the study was ended
early because there was little chance of demonstrating su-
periority with combination therapy including rifampin [43].
Rifaximin
Rifaximin is a nonabsorbable rifamycin derivative that
inhibits bacterial RNA synthesis. Theoretical advantages
include poor gastrointestinal tract absorption, intestinal lu-
men activity, and a low incidence for resistance. Rifaximin
achieves high colonic concentrations and may spare usual
enteric flora. It has a broad spectrum of activity against gram-
positive bacilli, gram-negative bacilli, aerobes, and anaer-
obes. Hence, it is an ideal drug used for traveler’s diarrhea.
The minimal inhibitory concentration (MIC) profile is su-
perior to that of metronidazole and vancomycin.
A small randomized study confirmed equivalence of ri-
faximin with oral vancomycin [44]. Three case series have
documented potential benefit with rifaximin to prevent CDI
recurrence [45–47]. In one case series of patients with re-
current CDI, a dose of rifaximin 400mg PO BID for two
weeks given immediately after the last course of oral van-
comycin resulted in cure for seven out of eight patients [48].
However, some concerns were raised regarding antimicrobial
resistance in one patient. An open label trial of rifaximin
(400mg PO three times daily [TID] for 10 d) as first-line
therapy in 13 hospitalized patients with CDI documented that
all eight patients who completed the study had completed
symptom resolution; one patient had recurrent infection
during a repeat hospitalization [49]. In a report of 32 patients
treated with rifaximin for recurrent C. difficile infection with
1 y follow up, 53% of patients had no relapse. The MIC value
of rifampin seemed to predict the response to rifaximin
treatment [50].
A multicenter double-blind randomized controlled
trial of rifaximin compared to vancomycin for C. difficile
(NCT00269399) was completed; final results are pending.
Rifaximin is currently approved by the FDA for travelers’
diarrhea (200mg PO TID for 3 d) caused by non-invasive
Table 3a. Guidelines for Treatment
of Initial Clostridium difficile Infection
Initial episode Recommended treatment
Mild-moderate CDI Metronidazole
500mg PO/IV TID1
-WBC < 15,000 cells/mm3 10–14 d
and
-creatinine < 1.5 · baseline
Severe CDI Vancomycin 125mg
PO QID (FDA approved)2
-WBC > 15,000 cells/mm3 10–14 d
or
-creatinine > 1.5 · baseline
Severe, complicated CDI Vancomycin 500mg
PO QID
-same as for severe CDI
and
– IV metronidazole
500mg IV q8h
Vancomycin 500mg
in 100mL NS q6h as
retention enema (if ileus)3
-hypotension/shock,
ileus, toxic megacolon,
perforation, need
for colectomy,
or ICU admission
Adapted from Cohen et al. [15].
1Neither oral nor parenteral metronidazole reach therapeutic
concentrations in normal, nondiarrheal stool.
2Vancomycin needs to be delivered enterally to have effect
3To perform vancomycin retention enemas, insert an 18-inch
foley catheter with 30mL balloon into rectum, inflate balloon,
instill vancomycin, clamp catheter for 60min, then deflate balloon
and remove catheter with balloon.
CDI =Clostridium difficile infection; PO = oral; IV = intravenous;
TID = 3 times daily; WBC =white blood cells; QID = 4 times daily;
FDA =U.S. Food and Drug Administration; q8h= every 8 h;
NS = normal saline; q6h= every 6 h; ICU = intensive care unit.
Table 3b. Guidelines for Treatment of Recurrent
Clostridium difficile Infection (CDI)
Recurrent disease Up to 65% recurrence rates
First
recurrence
Same treatment algorithm
as for initial episode CDI
-Recommend vancomycin if
WBC > 15 k or increasing serum
creatinine concentration (higher risk)
Second
recurrence
Vancomycin in a tapered
or pulsed regimen
-No metronidazole (neurotoxicity)
Adapted from Cohen et al. [15].
WBC =white blood cells.
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strains of Escherichia coli and for reduction in the risk of
overt hepatic encephalopathy recurrence (550mg PO BID)
in patients 18 y or older but is not approved for the treatment
of CDI.
Nitazoxanide
Nitazoxanide is synthetic nitrothiazolyl-salicylamide de-
rivative used to treat protozoan and helminthic infections.
This is also the only drug that is effective for cryptosporidi-
osis in patients who have acquired immune deficiency syn-
drome. Nitazoxanide blocks anaerobic metabolism of
eukaryocytes and inhibits C. difficile in vitro at low con-
centrations. Approximately two-thirds of the oral dose is
excreted in the stool as the active metabolite tizoxanide. In a
prospective, double-blind control trial, a 10-d course of ni-
tazoxanide 500mg POBIDwas as effective as metronidazole
in the treatment of CDI [51]. In a second prospective double-
blind study of nitazoxanide versus oral vancomycin, the
clinical response rate was no different (77% nitazoxanide vs.
74% vancomycin) [52]. An open-label study in 35 CDI pa-
tients reported an overall response rate of 66%. In these
FIG. 5. Suggested approach to treatment of recurrent Clostridium difficile infection (CDI). From Cocanour [35]. IV
Ig = intravenous immunoglobulin; MAB =monoclonal antibody.
FIG. 4. Treatment algorithm for management of Clostridium difficile infection. From Joseph et al. [31].
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studies, the drug was well tolerated, with no serious adverse
events reported.
Tigecycline
Tigecycline, a novel derivative of minocycline, has been
used off-label in critically ill patients with severe compli-
cated CDI whose infections did not respond to standard
therapies. A report of seven cases confirmed that six of the
seven patients were treated successfully with tigecycline
therapy with treatment duration of two to four weeks. None of
these patients experienced recurrence to date [53]. In vitro
studies demonstrated a 90% MIC range for tigecycline of
0.016–0.25mg/L for all C. difficile isolates. Tigecycline also
exhibited good fecal penetration because of primary biliary
excretion of unchanged drug, and as much as 59% of the dose
is recovered in feces following administration over 4 d in
health volunteers.
Monoclonal antibodies
One of the major incongruities in the management of CDI
is that antibiotics are the mainstay of treatment for this an-
tibiotic-associated condition. Non-antibiotic treatments such
as monoclonal antibodies would be a welcome addition or
replacement of current standard therapies.
The first Phase II human multicenter randomized double-
blind, placebo-controlled trial of two novel, neutralizing,
fully human monoclonal antibodies against C. difficile toxins
A and B had impressive results [54]. Recurrent infection
developed in 7% (seven of 101) of the antibody group
compared with 25% (25 of 99) in the placebo group, re-
flecting a relative reduction of 72%. Interestingly, there was
no effect on the duration or severity of the initial episode of
infection. The antibodies were not immunogenic and adverse
events were not different than placebo. The trial results are
consistent with previous studies showing that inadequate
circulating antibody levels against C. difficile toxins predis-
pose patients to symptomatic and recurrent infection, and
with observational data suggesting a benefit associated with
passive and active immunization for secondary prevention.
Although monoclonal antibodies will not be used for primary
treatment, they will likely play a role in patients at risk for
recurrent infection, and they may allow a reduction in the
duration of standard antimicrobial therapy for acute CDI
[55]. Additional Phase III human studies are underway ex-
amining the efficacy of monoclonal antibodies against toxins
A and B in C. difficile disease (Table 4).
Immunoglobulins
Immunoglobulins have been studied retrospectively with
some success in patients with severe and recurrent CDI.
Since an inability to mount a protective immune response to
C. difficile and its toxins appears to be responsible for sus-
ceptibility to recurrent infection [56,57], this treatment
strategy has somemerit. More than one-half of all adults have
circulating antibodies against C. difficile toxins and normal
pooled immunoglobulins can neutralize toxins A and B [58].
Intravenous pooled human immunoglobulin products have
been used off-label and on an ad hoc basis for passive im-
munotherapy. However, pharmacokinetic and efficacy data
for these products are not available. Variable results have
been reported with this treatment strategy [59–63]. No ran-
domized trial data are available.
Fecal transplantation
The use of fecal transplant from healthy donors is another
treatment modality under investigation. Stool slurries are
given via nasogastric tube or as enemas to CDI patients. A
recent study randomized patients (n = 43) with recurrent CDI
to receive one of three therapies: An initial vancomycin
regimen (500mg orally four times per day for 4 d), followed
by bowel lavage and subsequent infusion of a solution of
donor feces through a nasoduodenal tube; a standard van-
comycin regimen (500mg orally four times per day for 14 d);
or a standard vancomycin regimen with bowel lavage. The
primary end point was the resolution of diarrhea associated
with CDI without relapse after 10 wk. The study was stopped
early after an interim analysis documented that 81% of the
fecal transplantation cohort had resolution after the first in-
fusion, compared with 31% (oral vancomycin therapy alone)
and 23% (oral vancomycin with bowel lavage) in the other
experimental cohorts [64,65]. This study, although small and
unblinded, does confirm the efficacy of fecal transplantation
for recurrent CDI.
Active immunization
The C. difficile toxoid vaccine was well tolerated and
immunogenic in normal healthy subjects [66]. A report of
vaccine use in three patients with recurrent infection docu-
mented that none had a subsequent relapse [67].
Currently, two vaccine candidates against CDI are being
tested clinically. The more advanced program is that of
Sanofi-Pasteur (Lyon, France) with the toxoid ACAM-
CDIFF (NCT00772343 and NCT01230957). The vaccine
candidate is composed of a mixture of formalin-inactivated
toxin A and B that is given three times intramuscularly. The
vaccine has been shown to be safe, well tolerated, and im-
munogenic in healthy adults [68,69]. Two phase II studies are
currently being conducted in prophylactic and therapeutic
settings to better define the optimal dose and to tackle the
necessity of adsorbing the toxoids on aluminum salt [70].
Because the vaccine addresses an important unmet medical
need, ACAM-CDIFF has been fast-tracked by the FDA.
In parallel, Intercell (Vienna, Austria) is now testing the
safety, tolerability and immunogenicity of an anti-CDI vac-
cine candidate in an open-label, dose-escalating Phase I study
in healthy volunteers (NCT01296386). In this study, one
cohort includes individuals older than 65 y. The subunit vac-
cine developed by Intercell/Valneva consists of a recombi-
nant fusion protein containing a part of the receptor-binding
domain of toxins A and B administered with aluminum
salt and given three times intramuscularly [71,72]. Although
immunization appears promising, additional trials are war-
ranted [73].
Tolevamer, non-antibiotic polymer
Tolevamer is a toxin-binding polymer that binds to the
C. difficile toxin in the intestinal tract at doses of 3 to 6 g
daily. It has no antibiotic properties, does not alter normal gut
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Table 4. Studies of Human Monoclonal Antibodies Against Clostridium difficile Toxins A and B
Candidates
and sponsor
Therapeutic
agent Formulation
Development
stage
Patient study
cohorts Reference
Antitoxin A and
antitoxin
B monoclonal
antibodies
(Medarex and
Bristol-Myers
Squibb-Merck)
Antitoxin
A and B
fully human
monoclonal
antibodies
targeting the
receptor-
binding
domain of
the toxins
CDA1
(antitoxin A)
plus CDB1
(antitoxin B)
once at 10mg/kg
in parallel
to standard
antibiotics
Phase II
(completed)
200 patients
with
symptomatic
CDI
Lowy et al. N Engl J
Med 2010;362:197–205.
Phase II clinical study
giving the proof-of-
concept of the efficacy
of a combination of two
monoclonal antibodies
plus antibiotic treatment
in the prevention
of relapse.
Biologic
MK-3415
MKl-3415A,
MK-6072
Merck
MK-3415
(antitoxin A)
MK-6072
(antitoxin B)
or
MK-3415A
(combination
of the two
antibodies)
at a single
administration of
10mg/kg, with
antibiotic therapy
Phase III 1,600 patients
with
symptomatic
CDI and
under
antimicrobial
therapy
Primary
outcome measure
is CDI
recurrence
A Phase III, Randomized,
Double-Blind, Placebo-
Controlled, Adaptive
Design Study of the
Efficacy, Safety, and
Tolerability of a Single
Infusion of MK-3415
(Human Monoclonal
Antibody to Clostridium
Difficile Toxin A), MK-
6072 (Human Monoclo-
nal Antibody to
Clostridium Difficile
Toxin B), and MK-
3415A (Human
Monoclonal Antibodies
to C. difficile Toxin A
and Toxin B) in Patients
Receiving Antibiotic
Therapy for C. difficile
Infection (MODIFY I)
NCT01241552
Study enrollment
ongoing: October 2011 –
November 2014
Biologic
MK-6072
MK-3415A
Placebo
Merck
MK-6072
(antitoxin B)
or
MK-3415A
(combination
of the two
antibodies) at
a single
administration
of 10mg/kg,
with antibiotic
therapy
Phase III 1,200 patients
with
symptomatic
CDI receiving
SOC therapy
Primary
outcome
measure
is CDI
recurrence
A Phase III, Randomized,
Double-Blind, Placebo-
Controlled Study of the
Efficacy, Safety and
Tolerability of a Single
Infusion of MK-6072
(Human Monoclonal
Antibody to C. Difficile
Toxin B), and MK-
3415A (Human
Monoclonal Antibodies
to C. difficile Toxin A
and B) in Patients
Receiving Antibiotic
Therapy for C. difficile
Infection (MODIFY II)
NCT01513239
Study enrollment
ongoing: February 2012
– December 2014
CDI=Clostridum difficile infection; SOC = standard of care.
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flora, and would not result in the development of resistant
strains. It does not bind metronidazole or vancomycin. Early
phase II trials reported similar outcomes to standard therapy
in mild-to-moderate CDI, but Phase III clinical trials pub-
lished in 2009 reported that it did not reduce the duration or
magnitude of C. difficile toxin activity and further develop-
ment has been terminated [74–76].
Surgical Management
Timing of surgical consultation
Surgical consultation should occur early in the course of
disease in patients with severe and complicated C. difficile
colitis, as surgical decision making is challenging and the
clinical course of the disease is difficult to predict in any
individual patient. Early surgical consultation is re-
commended for the critically ill patient with CDI [77]. A
recent single-center study documented that survival rates
were higher in patients cared for by surgical versus non-
surgical departments, possibly because of earlier and more
frequent surgical intervention [78].
Furthermore, surgical consultation does not always rec-
ommend surgical intervention. A single-center case series
report of 47 patients with severe C. difficile colitis with
surgical consultation recommended initiation of an adju-
vant intracolonic vancomycin enema (1 g/500mL normal
saline every 6 h) protocol and 70% of patients responded
with complete resolution without need for surgery. Multi-
variable logistic regression confirmed that acidosis and
hypoalbuminemia were significantly associated with in-
complete response to intracolonic vancomycin enema
treatment [79].
Total abdominal colectomy
The indications for surgical management of patients with
CDI are not defined clearly. Most clinicians advocate surgical
intervention in patients with severe disease, worsening clin-
ical condition and in those with peritonitis or shock states.
Total abdominal colectomy was the standard surgical
procedure performed in these cases, but mortality rates were
Table 5. Proposed Indications for Ileostomy
with Antegrade Colonic Lavage
Suspected or established diagnosis of CDI plus
one or more of the following:
 Need for intensive care unit admission
 Hypotension necessitating vasopressor support
 Neurologic changes
 Respiratory failure necessitating mechanical ventilation
 Increasing white blood cell count > 20,000/mm3
 Lactate concentration > 5mmol/L
 Other signs of end-organ damage or new organ failureFIG. 6. Operative treatment for loop ileostomy and co-
lonic lavage for severe, complicated C. difficile associated
disease. When possible, laparoscopic exploration of the
colon and abdominal cavity is performed and a loop
ileostomy is created. The colon is then lavaged in an ante-
grade fashion through the ileostomy with a high volume (8
L) of polyethylene glycol 3350 or balanced electrolyte so-
lution and the effluent is collected via a rectal drainage tube.
A catheter is placed in the efferent limb of the ileostomy to
deliver vancomycin flushes in an antegrade fashion in the
postoperative period.
Table 6. Recommendations for Infection Control and Prevention of Clostridium difficile Infection (CDI)
 A hospital-based infection control program can help to decrease the incidence of CDI. (Conditional recommendation,
moderate-quality evidence)
 Routine screening for C. difficile in hospitalized patients without diarrhea is not recommended and asymptomatic carriers
should not be treated. (Strong recommendation, low-quality evidence)
 Antibiotic stewardship is recommended to reduce the risk of CDI. (Strong recommendation, high-quality evidence)
 Contact precautions for a patient with CDI should be maintained at a minimum until the resolution of diarrhea. (Strong
recommendation, high-quality evidence)
 Patients with known or suspected CDI should be placed in a private room or in a room with another patient with
documented CDI. (Strong recommendation, high-quality evidence)
 Hand hygiene and barrier precautions, including gloves and gowns, should be used by all health-care workers and visitors
entering the room of any patient with known or suspected CDI. (Strong recommendation, moderate-quality evidence)
 Single-use disposable equipment should be used for prevention of CDI transmission. Non-disposable medical equipment
should be dedicated to the patient’s room and other equipment should be thoroughly cleaned after use in a patient with
CDI. (Strong recommendation, moderate-quality evidence)
 Disinfection of environmental surfaces is recommended using an Environmental Protection Agency (EPA)-registered
disinfectant with C. difficile–sporicidal label claim or 5000 p.p.m. chlorine-containing cleaning agents in areas of
potential contamination by C. difficile. (Strong recommendation, high-quality evidence)
 Although there is moderate evidence that two probiotics (Lactobacillus rhamnosus GG and Saccharomyces boulardii)
decrease the incidence of antibiotic associated diarrhea, there is insufficient evidence that probiotics prevent C. difficile
infection. (Strong recommendation, low-quality evidence)
From Surawicz et al. [25]. (Reprinted by permission from Macmillan Publishers Ltd.)
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high [80,81] and most survivors required permanent ileost-
omywith long-term complications related to fluid losses from
the ileostomy. Common indications for colectomy include
colonic perforation, toxic megacolon with impending perfo-
ration, peritonitis, severe sepsis or septic shock, need for
vasopressor support, new end-organ dysfunction or failure,
and colitis refractory to medical management. All of these
factors also are significant predictors of mortality.
A systematic review and meta-analysis of outcomes fol-
lowing emergency surgery for C. difficile colitis included 31
studies (n = 1,433), and the most commonly performed sur-
gery was total colectomy with end-ileostomy (89%; 1,247 of
1,401 surgical procedures). When total colectomy was not
performed, additional bowel resection was required in 15.9%
of patients. The 30-d mortality rate was 41.3%. The strongest
predictors of post-operative death were those relating to pre-
operative physiologic status: pre-operative intubation, acute
renal failure, multiple organ failure, and shock requiring
vasopressors [82].
Diverting loop ileostomy and colonic irrigation
More recently, an alternative surgical procedure to total
abdominal colectomy has emerged with creation of a loop
ileostomy, intraoperative colonic lavage via the ileostomy,
and post-operative antegrade vancomycin flushes via the
ileostomy (Fig. 6). The initial report of this procedure in 42
patients documented that the procedure was accomplished
laparoscopically in 35 (83%) patients. The new treatment
strategy resulted in reduced mortality, compared with the au-
thors’ historical population who had undergone total abdom-
inalcolectomy(19%vs.50%,OR0.24;p= 0.006).Preservation
of the colon was achieved in 39 (93%) patients [83].
This new procedure is a potential surgical advance in the
treatment of severe life-threatening CDI. Proposed indi-
cations for this surgical procedure are listed in Table 5. A
single-institution prospective randomized trial is ongoing at
the Massachusetts General Hospital (NCT01441271) com-
paring ileal diversion and colonic lavage with total abdom-
inal colectomy for the treatment of fulminant C. difficile
colitis.
Infection Control
Transmission of C. difficile is usually person-to-person,
and via a fecal-oral route. The hands of healthcare workers
and environmental fomites (such as bedpans, commodes, and
rectal probes) are key players for spread of the bacterium and
spores in acute care facilities. Thus, the best mode of pre-
venting transmission is with the use of full contact isolation
precautions (e.g., gloves, barrier gowns, private rooms, and
disposable or dedicated supplies and equipment), as well as
good hand hygiene and environmental cleaning. Contact pre-
cautions should be maintained at least until diarrhea is re-
solved. It is important to note that alcohol-based solutions do
not killC. difficile spores, and thus handwashingwith soap and
water is required to prevent spread via healthcare workers’
hands [84]. Likewise, a bleach-based solution (5,000ppm
chlorine) or Environmental Protection Agency– registered
disinfectant with a C. difficile sporicidal claim is required to
kill spores in the environment. General guidelines for infection
control and prevention are summarized in Table 6.
Summary
C. difficile infection incidence and severity has grown
dramatically in the past two decades, gaining increased sig-
nificance as a clinically important disease entity. Treatment
modalities vary based on CDI classification with regards to
severity and timing of onset. The mainstay of medical
treatment remains metronidazole (preferred due to sub-
stantial cost differential) and oral/rectal vancomycin. Other
treatment modalities may be used in special circumstances,
and more trials are underway to evaluate adjunctive treatment
options such as monoclonal antibodies, vaccination, and fecal
transplant. Early surgical consultation in severe cases of CDI
and in patients with deteriorating clinical condition may be
life-saving. Diverting loop ileostomy for antegrade colonic
irrigation may allow for colonic preservation in the appro-
priate patient population. Infection control measures both at
the individual as well as institution levels are vital to miti-
gating the spread of CDI.
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